OTUD5

WARSAW, Poland, Dec. 5, 2022 /PRNewswire/ -- Molecure S.A. ("Molecure": WSE: MOC) a clinical stage biotechnology company using its world leading medicinal chemistry capabilities to discover first-in-class small molecule drug candidates that directly modulate unexplored protein and RNA targets to treat multiple incurable diseases, announces agenda topics and participating key opinion leaders for its virtual R&D Day. The webcast event will be hosted by Molecure on the 7th December 2022 at 13.30 - 16.30 CET / 12.30 – 15.30 BST/ 7.30 – 10.30 ET. The meeting is available here: The presentations by Key Opinion Leaders and Molecure management will showcase the scientific insights and clear clinical needs that underpin Molecure's pipeline programs. Agenda topics: 13.30-15.30 Molecure's Vision, Strategy and Pipeline OATD-01, Molecure's first in class chitinase inhibitor: Clinical evaluation in sarcoidosis and potential patient impact (Prof. Krenke) Landscape and therapy opportunity in sarcoidosis Clinical development plan Other opportunities in interstitial lung disease OATD-02, Molecure's novel dual arginase inhibitor: Pre-clinical activity in a broad range of cancers State of oncology in Poland (Prof. Szczylik) Clinical development plan 15.30-15.40 Break 15.40-16.30 Early-stage pipeline Deubiquitinating enzymes (DUBs) program including USP7 in oncology YKL40 in oncology University of Michigan collaboration in fibrosis mRNA platform Key Opinion Leader Presenters: Prof. Rafal Krenke, Pulmonologist, Head of Department of Internal Medicine, Pulmonary Diseases & Allergy, Medical University of Warsaw Prof. Cezary Szczylik, Oncologist, Head of the Department of Clinical Oncology and Chemotherapy Europejskie Centrum Zdrowia (European Health Center) Otwock Molecure S.A. Presenters: Dr Marcin Szumowski - CEO, President of the Board Dr Zbigniew Zasłona - VP Research Biology, Member of the Board Dr Samson Fung - Chief Medical Officer Dr Nicolas Beuzen - Director of Business Development and Licensing For further information, please contact: Molecure S.A. (PR & IR) Marta Borkowska Email: [email protected] +(48) 728 728 143 MEDiSTRAVA Consulting (Financial PR) Frazer Hall, David Dible, Sandi Greenwood, Eleanor Perkin [email protected] +44 (0)203 928 6900 About Molecure Molecure is a clinical stage biotechnology company that uses its world leading medicinal chemistry and biology capabilities to discover and develop first-in-class small molecule drug candidates that directly modulate the function of underexplored protein and RNA targets to treat multiple incurable diseases. Molecure has generated a diverse pipeline of eight distinct programs with the support of leading academic life science institutions globally, including Yale University, Rutgers University, the Flemish Institute for Biotechnology (VIB) in Ghent, the University of Michigan and the International Institute of Molecular and Cell Biology in Warsaw (IIMCB). Molecure's most advanced in-house drug candidate is OATD-01, a first-in-class dual chitinase inhibitor for the treatment of interstitial lung diseases, such as sarcoidosis and idiopathic pulmonary fibrosis, that is Phase II ready. A Phase II trial in patients with sarcoidosis is expected to start in 2023. Our second proprietary candidate is OATD-02, an oral, potent and selective first-in-class, dual arginase inhibitor (ARG1 and ARG2) for the treatment of cancer. Molecure's headquarters and laboratories are located in Warsaw, Poland with an additional laboratory facility in Łódź. The company is listed on the Warsaw Stock Exchange (ticker: MOC). For more information, please visit LinkedIn: Molecure | Twitter: @molecure_sa | YouTube: Molecure SA SOURCE Molecure

Scientists have revealed two enzymes that regulate protein degradation of proteins in the cell membrane of plants, and established the roles they play in plant growth and development. Scientists have revealed two enzymes that regulate protein degradation of proteins in the cell membrane of plants, and established the roles they play in plant growth and development. Ubiquitin is a small regulatory protein found in most cells of eukaryotic organisms. It is vital to altering the function of other proteins, and is most notably involved in protein degradation and protein localization within the cell. Ubiquitin regulates these functions by attaching to and detaching from the target protein, a process called ubiquitination. Scientists from Japan, Belgium and the USA, led by Associate Professor Takeo Sato at Hokkaido University, have discovered the first examples of deubiquitinating enzymes in plants that act on proteins in the cell membrane of the cell. Their findings, published in the journal EMBO Reports, detail the function of these proteins. The addition of ubiquitin to target proteins is catalysed by enzymes called ubiquitin ligases, and the reverse process, removal of ubiquitin from target proteins, is catalysed by deubiquitinating enzymes (DUBs). It was not known which plant DUBs were able to directly remove ubiquitin from membrane proteins. This lack of knowledge meant that the regulation of membrane protein stability was not fully understood. The team demonstrated that two of the Arabidopsis thaliana DUBs, UBP12 and UBP13, directly target the cell membrane-localized plant hormone receptor known as BRI1. BRI1 is vital for the detection of brassinosteroids (BRs), steroidal phytohormones that are essential for growth and development. Typically, when BRI1 detects BR, it triggers a pathway that regulates gene expression in the nucleus. The abundance of cellular BRI1 is crucial to precisely mediate BR signal, although the regulatory mechanism for how BRI1 abundance is optimized (fine-tuned) in the cells was unclear. The scientists demonstrated that UBP12 and UBP13 de-ubiquitinated and stabilized BRI1. In their experiments, they showed that Arabidopsis thaliana plants that lacked the ability to express UBP12 and UBP13 were severely dwarfed and distinctly less sensitive to BRs. When a mutant BRI1 -- which could not be ubiquitinated -- was introduced into these UBP12 and UBP13-deficient plants, growth defects were partially restored. Specifically, UBP12 and UBP13 target and act on ubiquitinated BRI1. The study showed that UBP12 and UBP13 are key regulators of plant growth via their interaction with BRI1. The study also provided insight into how membrane protein stability is maintained; however, further research is required to fully understand the dynamics of BRI1 within the cell. Finally, the findings provide evidence that plant DUBs have roles similar to those of mammalian DUBs.